rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GNBT *******

3.572 Posts
Pagina: «« 1 ... 130 131 132 133 134 ... 179 »» | Laatste | Omlaag ↓
  18. [verwijderd] 14 juni 2007 16:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    uit ervaring kan ik zeggen dat die patenten geen koers stijging opleveren.

    WORCESTER, MA--(MARKET WIRE)--Jun 14, 2007 -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded two new United States patents strengthening its core vaccine technology platform. The first patent, titled Ii-Key/Antigenic Epitope Hybrid Peptide Vaccine, and the second patent, titled Hybrid Peptides Modulate the Immune Response, both help secure the novel Antigen Express vaccine technology platform which is the foundation for a number of vaccine products presently in clinical development.
  19. [verwijderd] 14 juni 2007 16:34

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Generex Biotechnology Awarded New U.S. Patents for Its Core Vaccine Technologies



    Last Update: 10:17 AM ET Jun 14, 2007


    WORCESTER, MA, Jun 14, 2007 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (GNBT : generex biotechnology cp del com
    News , chart , profile , more
    Last: 1.89-0.03-1.56%

    10:18am 06/14/2007

    Delayed quote dataAdd to portfolio
    Analyst
    Create alertInsider
    Discuss
    Financials
    Sponsored by:
    GNBT1.89, -0.03, -1.6%) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded two new United States patents strengthening its core vaccine technology platform. The first patent, titled Ii-Key/Antigenic Epitope Hybrid Peptide Vaccine, and the second patent, titled Hybrid Peptides Modulate the Immune Response, both help secure the novel Antigen Express vaccine technology platform which is the foundation for a number of vaccine products presently in clinical development.
    Proprietary immunotherapeutic cancer vaccines as well as prophylactic vaccines for infectious disease derive increased protection under these patents. The most advanced product is an immunotherapeutic vaccine that has entered Phase II clinical trials in breast cancer patients. The same compound is being tested in a Phase I clinical trial in prostate cancer patients. In addition, other hybrid peptide vaccines, based upon the same technology, are being tested in a Phase I clinical trial for their ability to generate an immune response against the potentially pandemic H5N1 avian influenza virus. To date, these types of epitope hybrid peptide vaccines have been tested in over 115 individuals and appear to be safe and well-tolerated.
    The increased activity of peptide vaccines designed using this technology is the result of their ability to potently stimulate CD4+ T helper cells to recognize specific pathogenic agents. T helper cells play a critical role in enabling the immune system to recognize novel agents and establishing immunological 'memory.'
3.572 Posts
Pagina: «« 1 ... 130 131 132 133 134 ... 179 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.019
AB InBev 2 5.505
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.700
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.714
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.866
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.339
Air France - KLM 1.025 35.047
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.871
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.266
AMG 971 133.397
AMS 3 73
Amsterdam Commodities 305 6.691
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.008
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.780
Arcelor Mittal 2.033 320.724
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.305
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.188
ASML 1.766 107.522
ASR Nederland 21 4.496
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.675
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392